High levels of SOCS2 was identified as an adverse prognostic characteristic of acute myeloid leukemia (AML) and ALL, such as those with MLL rearrangement or BCR/ABL fusions (Hansen et al., 2013; Vitali et al., 2015). The gene discussed is SOCS2; the disease is acute myeloid leukemia.